{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:58:05Z","timestamp":1790456285805,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["COVID-2020-12371675"],"award-info":[{"award-number":["COVID-2020-12371675"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente - Linea 1 e Linea 2"],"award-info":[{"award-number":["Ricerca Corrente - Linea 1 e Linea 2"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-\u03b3 production in 216 PLWH on ART with advanced disease (CD4 count &lt;200\u2009cell\/mm<jats:sup>3<\/jats:sup> and\/or previous AIDS) receiving the third dose of a mRNA vaccine (BNT162b2 or mRNA-1273) after a median of 142 days from the second dose. Median age is 54 years, median CD4 nadir 45\u2009cell\/mm<jats:sup>3<\/jats:sup> (20\u2013122), 93% HIV-RNA\u2009&lt;\u200950\u2009c\/mL. In 68% of PLWH at least one side-effect, generally mild, is recorded. Humoral response after the third dose was strong and higher than that achieved with the second dose (&gt;2 log<jats:sub>2<\/jats:sub> difference), especially when a heterologous combination with mRNA-1273 as third shot is used. In contrast, cell-mediated immunity remain stable. Our data support usefulness of third dose in PLWH currently receiving suppressive ART who presented with severe immune dysregulation.<\/jats:p>","DOI":"10.1038\/s41467-022-32263-7","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T13:05:44Z","timestamp":1661173544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6944-0686","authenticated-orcid":false,"given":"Alessandra","family":"Vergori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cozzi Lepri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Cicalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Matusali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Bordoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Lanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Meschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Iannazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0240-7504","authenticated-orcid":false,"given":"Valentina","family":"Mazzotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Colavita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Mastrorosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Cimini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7698-1103","authenticated-orcid":false,"given":"Davide","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"De Pascale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Marani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Gall\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AnnaRosa","family":"Garbuglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9819-236X","authenticated-orcid":false,"given":"Concetta","family":"Castilletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Puro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Agrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Vaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"HIV-VAC study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Amendola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Bellagamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Bettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia","family":"Bordi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Camici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Casetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Costantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Cristofanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"D\u2019Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"D\u2019Aquila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"De Zottis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"de Pascale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Francalancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Fusto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Gagliardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Gramigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germana","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Grilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Grisetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Iafrate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Lapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Lorenzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Marani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erminia","family":"Masone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Marongiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Mondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Notari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Ottou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Paulicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Pinnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Maddalena","family":"Plazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Possi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Tartaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"32263_CR1","unstructured":"WHO Coronavirus (COVID19) Dashboard. Available at: https:\/\/covid19.who.int."},{"key":"32263_CR2","doi-asserted-by":"publisher","first-page":"eabd1525","DOI":"10.1126\/scitranslmed.abd1525","volume":"13","author":"WC Koff","year":"2021","unstructured":"Koff, W. C. et al. Development and deployment of COVID-19 vaccines for those most vulnerable. Sci. Transl. Med. 13, eabd1525 (2021). PMID: 33536277.","journal-title":"Sci. Transl. Med."},{"key":"32263_CR3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal, J. et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N. Engl. J. Med. 385, 585\u2013594 (2021). Epub 2021 Jul 21. PMID: 34289274; PMCID: PMC8314739.","journal-title":"N. Engl. J. Med."},{"key":"32263_CR4","doi-asserted-by":"publisher","unstructured":"Nasreen, S. et al. Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. medRxiv. 06.28.21259420; https:\/\/doi.org\/10.1101\/2021.06.28.21259420. (2021)","DOI":"10.1101\/2021.06.28.21259420"},{"key":"32263_CR5","unstructured":"Comirnaty and Spikevax: EMA recommendations on extra doses and boosters. Available at: https:\/\/www.ema.europa.eu\/en\/news\/comirnaty-spikevax-ema-recommendations-extra-doses-boosters."},{"key":"32263_CR6","unstructured":"CDC Expands COVID-19 Booster Recommendations. https:\/\/www.cdc.gov\/media\/releases\/2021\/s1129-booster-recommendations.html."},{"key":"32263_CR7","doi-asserted-by":"publisher","unstructured":"Choi, A. et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-021-01527-y. (2021) Epub ahead of print. PMID: 34526698.","DOI":"10.1038\/s41591-021-01527-y"},{"key":"32263_CR8","doi-asserted-by":"publisher","unstructured":"Meng, B. et al. CITIID-NIHR BioResource COVID-19 Collaboration, The Genotype to Phenotype Japan(G2P-Japan) Consortium, Choi J, Lee JH, Mlcochova P, James L, Doffinger R, Thukral R, Sato K, Gupta RK. SARS CoV-2 Omicron spike mediated immune escape, infectivity and cell-cell fusion. bioRxiv; https:\/\/doi.org\/10.1101\/2021.12.17.473248.","DOI":"10.1101\/2021.12.17.473248"},{"key":"32263_CR9","doi-asserted-by":"publisher","unstructured":"Dejnirattisai, W. et al. Com-COV2 Study Group. Reduced neutralization of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum. medRxiv preprint https:\/\/doi.org\/10.1101\/2021.12.10.21267534.","DOI":"10.1101\/2021.12.10.21267534"},{"key":"32263_CR10","doi-asserted-by":"publisher","unstructured":"Planas, D. et al. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization. bioRxiv preprint https:\/\/doi.org\/10.1101\/2021.12.14.472630; this version posted December 15, 2021.","DOI":"10.1101\/2021.12.14.472630"},{"key":"32263_CR11","doi-asserted-by":"publisher","unstructured":"Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell, 2021; PII: S0092-8674(21)01496-3; https:\/\/doi.org\/10.1016\/j.cell.2021.12.033.","DOI":"10.1016\/j.cell.2021.12.033"},{"key":"32263_CR12","doi-asserted-by":"publisher","first-page":"e2095","DOI":"10.1093\/cid\/ciaa1605","volume":"73","author":"AM Geretti","year":"2021","unstructured":"Geretti, A. M. et al. Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study. Clin. Infect. Dis. 73, e2095\u2013e2106 (2021). PMID: 33095853; PMCID: PMC7665382.","journal-title":"Clin. Infect. Dis."},{"key":"32263_CR13","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3018(20)30305-2","volume":"8","author":"K Bhaskaran","year":"2021","unstructured":"Bhaskaran, K. et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet Hiv. 8, e24\u2013e32 (2021). Epub 2020 Dec 11. PMID: 33316211; PMCID: PMC7773630.","journal-title":"Lancet Hiv."},{"key":"32263_CR14","doi-asserted-by":"publisher","first-page":"e2037069","DOI":"10.1001\/jamanetworkopen.2020.37069","volume":"4","author":"JM Tesoriero","year":"2021","unstructured":"Tesoriero, J. M. et al. COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State. JAMA Netw. Open. 4, e2037069 (2021). PMID: 33533933; PMCID: PMC7859843.","journal-title":"JAMA Netw. Open."},{"key":"32263_CR15","doi-asserted-by":"crossref","unstructured":"Spinelli, M. A. et al. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralization antibody titres after infection, compared by HIV status: a matched case-control observational study. Lancet HIV. 20218:e334-e341. Epub 2021 Apr 29. PMID: 33933189; PMCID: PMC8084354.","DOI":"10.1016\/S2352-3018(21)00072-2"},{"key":"32263_CR16","doi-asserted-by":"publisher","unstructured":"Fehr, D. et al. Characterization of people living with HIV in a Montreal-based tertiary care center with COVID-19 during the first wave of the pandemic. AIDS Care. 20211-7. https:\/\/doi.org\/10.1080\/09540121.2021.1904500. Epub ahead of print. PMID: 33779425.","DOI":"10.1080\/09540121.2021.1904500"},{"key":"32263_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/cid\/ciq110","volume":"52","author":"AN Sheth","year":"2011","unstructured":"Sheth, A. N., Althoff, K. N. & Brooks, J. T. Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literature. Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am. 52, 219\u2013227 (2011).","journal-title":"Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am."},{"key":"32263_CR18","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S2352-3018(21)00103-X","volume":"8","author":"J Frater","year":"2021","unstructured":"Frater, J. et al. Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2\/3 clinical trial. Lancet Hiv. 8, e474\u2013e485 (2021). Epub 2021 Jun 18. PMID: 34153264; PMCID: PMC8213361.","journal-title":"Lancet Hiv."},{"key":"32263_CR19","doi-asserted-by":"publisher","unstructured":"Ogbe, A. et al. Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV \u2013 responses to SARS-CoV-2, variants of concern and circulating coronaviruses. medRxiv 2021.09.28.21264207; https:\/\/doi.org\/10.1101\/2021.09.28.21264207","DOI":"10.1101\/2021.09.28.21264207"},{"key":"32263_CR20","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.cmi.2021.07.031","volume":"27","author":"I Levy","year":"2021","unstructured":"Levy, I. et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clin. Microbiol Infect. 27, 1851\u20131855 (2021). Epub 2021 Aug 24. PMID: 34438069; PMCID: PMC8382485.","journal-title":"Clin. Microbiol Infect."},{"key":"32263_CR21","doi-asserted-by":"publisher","unstructured":"Woldemeskel, B. A. et al. The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living with HIV. Clin Infect Dis. (2021)ciab648. https:\/\/doi.org\/10.1093\/cid\/ciab648. Epub ahead of print. PMID: 34293114; PMCID: PMC8406881.","DOI":"10.1093\/cid\/ciab648"},{"key":"32263_CR22","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1097\/QAD.0000000000003017","volume":"35","author":"JA Ruddy","year":"2021","unstructured":"Ruddy, J. A. et al. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV. AIDS 35, 2399\u20132401 (2021). PMID: 34261097.","journal-title":"AIDS"},{"key":"32263_CR23","doi-asserted-by":"publisher","unstructured":"Brumme, Z. L. et al. Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. medRxiv [Preprint]. 20212021.10.03.21264320. https:\/\/doi.org\/10.1101\/2021.10.03.21264320. PMID: 34671779; PMCID: PMC8528088.","DOI":"10.1101\/2021.10.03.21264320"},{"key":"32263_CR24","doi-asserted-by":"crossref","unstructured":"Lombardi, A. et al. Anti-spike antibodies and neutralization antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: a prospective single centre cohort study. The Lancet Regional Health \u2013 Europe, Volume 0, Issue 0, 100287.","DOI":"10.1016\/j.lanepe.2021.100287"},{"key":"32263_CR25","doi-asserted-by":"publisher","unstructured":"Aledo, M. G. et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 and BNT162b2 vaccines in people living with HIV. AIDS. https:\/\/doi.org\/10.1097\/QAD.0000000000003161. (2022) Epub ahead of print. PMID: 34999608.","DOI":"10.1097\/QAD.0000000000003161"},{"key":"32263_CR26","doi-asserted-by":"publisher","unstructured":"Jedicke, N. et al. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy. HIV Med. https:\/\/doi.org\/10.1111\/hiv.13202. (2021) Epub ahead of print. PMID: 34725907; PMCID: PMC8652991.","DOI":"10.1111\/hiv.13202"},{"key":"32263_CR27","doi-asserted-by":"publisher","unstructured":"Antinori, A. et al. HIV-VAC Study Group. Humoral and cellular immune response elicited by mRNA vaccination against SARS-CoV-2 in people living with HIV (PLWH) receiving antiretroviral therapy (ART) according with current CD4 T-lymphocyte count. Clin Infect Dis. ciac238. https:\/\/doi.org\/10.1093\/cid\/ciac238. (2022) Epub ahead of print. PMID: 35366316.","DOI":"10.1093\/cid\/ciac238"},{"key":"32263_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26137-7","volume":"12","author":"A Alrubayyi","year":"2021","unstructured":"Alrubayyi, A. et al. Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV. Nat. Commun. 12, 5839 (2021).","journal-title":"Nat. Commun."},{"key":"32263_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","volume":"596","author":"JS Turner","year":"2021","unstructured":"Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596, 109\u2013113 (2021). Epub 2021 Jun 28. PMID: 34182569.","journal-title":"Nature"},{"key":"32263_CR30","doi-asserted-by":"publisher","unstructured":"Spinelli, M. A. et al. Differences in Post-mRNA Vaccination SARS-CoV-2 IgG Concentrations and Surrogate Virus Neutralization Test Response by HIV Status and Type of Vaccine: a Matched Case-Control Observational Study. Clin. Infect. Dis. ciab1009. https:\/\/doi.org\/10.1093\/cid\/ciab1009. (2021) Epub ahead of print. PMID: 34864962; PMCID: PMC8689738.","DOI":"10.1093\/cid\/ciab1009"},{"key":"32263_CR31","doi-asserted-by":"publisher","unstructured":"Bagacean, C. et al. Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia. Blood Adv. bloodadvances.2021006215. https:\/\/doi.org\/10.1182\/bloodadvances.2021006215. (2021) Epub ahead of print. PMID: 34844264.","DOI":"10.1182\/bloodadvances.2021006215"},{"key":"32263_CR32","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.3390\/jcm10215113","volume":"10","author":"FP Tillmann","year":"2021","unstructured":"Tillmann, F. P. et al. P. Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study. J. Clin. Med. 10, 5113 (2021). PMID: 34768631; PMCID: PMC8584296.","journal-title":"J. Clin. Med."},{"key":"32263_CR33","doi-asserted-by":"publisher","unstructured":"Ehmsen, S. et al. Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination. Cancer Cell. S1535-6108(22)00063-0. https:\/\/doi.org\/10.1016\/j.ccell.2022.02.011. (2022) Epub ahead of print. PMID: 35216675; PMCID: PMC8867110.","DOI":"10.1016\/j.ccell.2022.02.011"},{"key":"32263_CR34","doi-asserted-by":"publisher","unstructured":"Rottenberg, Y. et al. Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2021.6764. (2021) Epub ahead of print. PMID: 34812840.","DOI":"10.1001\/jamaoncol.2021.6764"},{"key":"32263_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1146\/annurev-med-042909-093756","volume":"62","author":"SG Deeks","year":"2011","unstructured":"Deeks, S. G. HIV infection, inflammation, immunosenescence, and aging. Annu Rev. Med 62, 141\u2013155 (2011). PMID: 21090961; PMCID: PMC3759035.","journal-title":"Annu Rev. Med"},{"key":"32263_CR36","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1097\/00002030-200009080-00007","volume":"14","author":"M Plana","year":"2000","unstructured":"Plana, M. et al. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS 14, 1921\u20131933 (2000). PMID: 10997396.","journal-title":"AIDS"},{"key":"32263_CR37","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1097\/00002030-200012010-00003","volume":"14","author":"GR Kaufmann","year":"2000","unstructured":"Kaufmann, G. R. et al. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS 14, 2643\u20132651 (2000). PMID: 11125882.","journal-title":"AIDS"},{"key":"32263_CR38","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.amjmed.2018.12.011","volume":"132","author":"F El Chaer","year":"2019","unstructured":"El Chaer, F. & El Sahly, H. M. Vaccination in the Adult Patient Infected with HIV: A Review of Vaccine Efficacy and Immunogenicity. Am. J. Med. 132, 437\u2013446 (2019).","journal-title":"Am. J. Med."},{"key":"32263_CR39","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/cid\/cit937","volume":"58","author":"S Kern\u00e9is","year":"2014","unstructured":"Kern\u00e9is, S. et al. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clin. Infect. Dis. 58, 1130\u20131139 (2014). Epub 2014 Jan 10. PMID: 24415637; PMCID: PMC4761378.","journal-title":"Clin. Infect. Dis."},{"key":"32263_CR40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/QCO.0b013e328334fec4","volume":"23","author":"AM Geretti","year":"2010","unstructured":"Geretti, A. M. & Doyle, T. Immunization for HIV-positive individuals. Curr. Opin. Infect. Dis. 23, 32\u201338 (2010).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"32263_CR41","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.immuni.2021.08.001","volume":"54","author":"MM Painter","year":"2021","unstructured":"Painter, M. M. et al. Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity 54, 2133\u20132142.e3 (2021). Epub 2021 Aug 13. PMID: 34453880; PMCID: PMC8361141.","journal-title":"Immunity"},{"key":"32263_CR42","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/jid.2008.286","volume":"129","author":"D Cain","year":"2009","unstructured":"Cain, D., Kondo, M., Chen, H. & Kelsoe, G. Effects of acute and chronic inflammation on B-cell development and differentiation. J. Invest Dermatol. 129, 266\u2013277 (2009). PMID: 19148216; PMCID: PMC2778726.","journal-title":"J. Invest Dermatol."},{"key":"32263_CR43","doi-asserted-by":"publisher","unstructured":"Moro-Garc\u00eda, M. A., Mayo, J. C., Sainz, R. M. & Alonso-Arias, R. Influence of Inflammation in the Process of T Lymphocyte Differentiation: Proliferative, Metabolic, and Oxidative Changes. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2018.00339. (2018)","DOI":"10.3389\/fimmu.2018.00339"},{"key":"32263_CR44","doi-asserted-by":"publisher","unstructured":"Naranbhai, V. et al. Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines. medRxiv [Preprint]. 20212021.07.18.21260732. https:\/\/doi.org\/10.1101\/2021.07.18.21260732. PMID: 34671780; PMCID: PMC8528089.","DOI":"10.1101\/2021.07.18.21260732"},{"key":"32263_CR45","doi-asserted-by":"publisher","unstructured":"Dickerman, B. A. et al. Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans. NEJM. https:\/\/doi.org\/10.1056\/NEJMoa2115463. (2021)","DOI":"10.1056\/NEJMoa2115463"},{"key":"32263_CR46","doi-asserted-by":"publisher","unstructured":"Munro, A. P. S. et al. COV-BOOST study group. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomized, controlled, phase 2 trial. Lancet. S0140-6736(21)02717-3. https:\/\/doi.org\/10.1016\/S0140-6736(21)02717-3. (2021) Epub ahead of print. PMID: 34863358.","DOI":"10.1016\/S0140-6736(21)02717-3"},{"key":"32263_CR47","doi-asserted-by":"publisher","unstructured":"Keeton, R. et al. SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron. MedRxiv. https:\/\/doi.org\/10.1101\/2021.12.26.21268380.","DOI":"10.1101\/2021.12.26.21268380"},{"key":"32263_CR48","doi-asserted-by":"publisher","unstructured":"Tarke et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. bioRxiv [Preprint]. 20202020.12.08.416750. https:\/\/doi.org\/10.1101\/2020.12.08.416750. Update in: Cell Rep Med. (2021) Jan 26; 100204. PMID: 33330869; PMCID: PMC7743077.","DOI":"10.1101\/2020.12.08.416750"},{"key":"32263_CR49","doi-asserted-by":"publisher","unstructured":"Cele, S. et al A. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv preprint https:\/\/doi.org\/10.1101\/2021.12.08.21267417.","DOI":"10.1101\/2021.12.08.21267417"},{"key":"32263_CR50","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020). C4591001 Clinical Trial GroupEpub 2020 Dec 10. PMID: 33301246; PMCID: PMC7745181.","journal-title":"N. Engl. J. Med."},{"key":"32263_CR51","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021). COVE Study GroupEpub 2020 Dec 30. PMID: 33378609; PMCID: PMC7787219.","journal-title":"N. Engl. J. Med."},{"key":"32263_CR52","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","volume":"385","author":"HM El Sahly","year":"2021","unstructured":"El Sahly, H. M. et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N. Engl. J. Med. 385, 1774\u20131785 (2021). COVE Study GroupEpub 2021 Sep 22. PMID: 34551225; PMCID: PMC8482810.","journal-title":"N. Engl. J. Med."},{"key":"32263_CR53","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3390\/microorganisms9061315","volume":"9","author":"C Agrati","year":"2021","unstructured":"Agrati, C. et al. Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine. Microorganisms 9, 1315 (2021). On Behalf Of The Inmi Covid-Vaccine Study GroupPMID: 34208751; PMCID: PMC8235087.","journal-title":"Microorganisms"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32263-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32263-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32263-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T18:44:00Z","timestamp":1669315440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32263-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["32263"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-32263-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]},"assertion":[{"value":"7 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4922"}}